Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis

NCT05986162 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Dermatomyositis, Adult Type

Interventions

DRUG: Itolizumab

Sponsor

Biotech Pharmaceutical Co., Ltd.